BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Moodys
McKesson
US Army
Cipla
Daiichi Sankyo
Teva
Johnson and Johnson
Fish and Richardson
Mallinckrodt
Chubb

Generated: January 23, 2018

DrugPatentWatch Database Preview

Details for Patent: RE44599

« Back to Dashboard

Which drugs does patent RE44599 protect, and when does it expire?

Patent RE44599 protects ZYDELIG and is included in one NDA.

This patent has twenty-six patent family members in eighteen countries.
Summary for Patent: RE44599
Title:Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta
Abstract: Compounds that inhibit P13K.delta. activity, including compounds that selectively inhibit P13K.delta. activity, are disclosed. Methods of inhibiting phosphatidylinositol 3-kinase delta isoform (P13K.delta.) activity, and methods of treating diseases, such as disorders of immunity and inflammation in which P13K.delta. plays a role in leukocyte function, using the compounds also are disclosed.
Inventor(s): Fowler; Kerry W. (Seattle, WA), Huang; Danwen (Sammamish, WA), Kesicki; Edward A. (Bothell, WA), Ooi; Hua Chee (Kirkland, WA), Oliver; Amy (Bothell, WA), Ruan; Fuqiang (Bellevue, WA), Treiberg; Jennifer (Redmond, WA), Puri; Kamal Deep (Lynnwood, WA)
Assignee: ICOS Corporation (Indianapolis, IN)
Application Number:13/730,276
Patent Claim Types:
see list of patent claims
Use; Device;

Drugs Protected by US Patent RE44599

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Gilead Sciences Inc ZYDELIG idelalisib TABLET;ORAL 205858-001 Jul 23, 2014 RX Yes No ➤ Subscribe ➤ Subscribe FOR THE TREATMENT OF PATIENTS WITH CLL, FL, OR SLL ➤ Subscribe
Gilead Sciences Inc ZYDELIG idelalisib TABLET;ORAL 205858-001 Jul 23, 2014 RX Yes No ➤ Subscribe ➤ Subscribe FOR THE TREATMENT OF PATIENTS WITH RELAPSED FOLLICULAR B-CELL NON-HODGKIN LYMPHOMA OR [RELAPSED] SMALL LYMPHOCYTIC LYMPHOMA ➤ Subscribe
Gilead Sciences Inc ZYDELIG idelalisib TABLET;ORAL 205858-002 Jul 23, 2014 RX Yes Yes ➤ Subscribe ➤ Subscribe FOR THE TREATMENT OF PATIENTS WITH RELAPSED FOLLICULAR B-CELL NON-HODGKIN LYMPHOMA OR [RELAPSED] SMALL LYMPHOCYTIC LYMPHOMA ➤ Subscribe
Gilead Sciences Inc ZYDELIG idelalisib TABLET;ORAL 205858-002 Jul 23, 2014 RX Yes Yes ➤ Subscribe ➤ Subscribe FOR THE TREATMENT OF PATIENTS WITH CLL, FL, OR SLL ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent RE44599

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,932,260 Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta ➤ Subscribe
9,149,477 5-fluoro-3-phenyl-2-[1-(9h-purin-6-ylamino)propyl]-3h-quinazolin-4-one as an inhibitor of human phosphatidylinositol 3-kinase delta ➤ Subscribe
8,980,901 5-fluoro-3-phenyl-2[1-(9H-purin-6-ylamino)propyl]-3H-quinazolin-4-one and 6-fluoro-3-phenyl-2-[1-(9H-purin-6-ylamino)ethyl]-3H-quinazolin-4-one as inhibitors of human phosphatidylinositol 3-kinase delta ➤ Subscribe
8,993,583 5-fluoro-3-phenyl-2-[1-(9H-purin-6-ylamino)propyl]-3H-quinazolin-4-one and 6-fluoro-3-phenyl-2-[1-(9H-purin-6-ylamino)ethyl]-3H-quinazolin-4-one as inhibitors of human phosphatidylinositol 3-kinase delta ➤ Subscribe
8,207,153 Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta ➤ Subscribe
8,586,597 6-fluoro-3-phenyl-2-[1-(9H-purin-6-ylamino)ethyl]-3H-quinazolin-4-one as an inhibitor of human phosphatidylinositol 3-kinase delta ➤ Subscribe
8,779,131 6-fluoro-3-phenyl-2-[1-(9H-purin-6-ylamino)-ethyl]-3H-quinazolin-4-one as an inhibitor of human phosphatidylinositol 3-kinase delta ➤ Subscribe
RE44638 Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent RE44599

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2005245875 ➤ Subscribe
Australia 2009230739 ➤ Subscribe
Canada 2566609 ➤ Subscribe
China 101031569 ➤ Subscribe
China 102229609 ➤ Subscribe
Cyprus 1118493 ➤ Subscribe
Cyprus 1118516 ➤ Subscribe
Denmark 1761540 ➤ Subscribe
Denmark 2612862 ➤ Subscribe
European Patent Office 1761540 ➤ Subscribe PA2017004 Lithuania ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Federal Trade Commission
AstraZeneca
US Army
UBS
Baxter
US Department of Justice
Citi
Farmers Insurance

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot